Black/white differences in treatment and survival among women with stage IIIB–IV breast cancer at diagnosis: a US population-based study
- 114 Downloads
Non-Hispanic black (NHB) women with breast cancer have poorer survival than non-Hispanic white (NHW) women. Although NHB women are more often diagnosed at later stages, it is less established whether racial disparities exist among women diagnosed with late-stage breast cancer, particularly when care is provided in the community setting.
Treatment and survival were examined by race/ethnicity among women diagnosed in 2012 with stage IIIB–IV breast cancer using the National Cancer Institute’s population-based Patterns of Care Study. Medical records were re-abstracted and treating physicians were contacted to verify therapy. Vital status was available through 2014.
A total of 533 women with stage IIIB–C and 625 with stage IV tumors were included; NHW women comprised about 70% of each group. Among women with stage IIIB–C disease, racial/ethnicity variations in systemic treatment were not observed but there was a borderline association indicating worse all-cause mortality among NHB women (hazard ratio 1.52; 95% confidence interval (CI) 0.96–2.41). In contrast, among women with stage IV disease, borderline associations indicating NHB women were more likely to receive chemotherapy (OR 1.44, 95% CI 0.90–2.30) and, among those with hormone receptor-positive tumors, less likely to receive endocrine therapy (OR 0.60, 95% CI 0.35–1.04). All-cause mortality did not vary by race/ethnicity for stage IV disease (hazard ratio 0.92; 95% CI 0.68–1.25).
More research is needed to identify additional factors associated with the potential survival disparities among women with stage IIIB–C disease and potential treatment disparities among women with stage IV disease.
KeywordsBreast cancer Disparity Chemotherapy Endocrine therapy Survival HER2
This study was made possible through the efforts of the Principal Investigators and the personnel at the Surveillance, Epidemiology, and End Results registries.
National Cancer Institute contracts: HHSN261201000024C; HHSN261201000025C, HHSN261201000032C, HHSN261201000027C, HHSN261201000026C, HHSN261201000140C, HHSN261201000037C, HHSN261201000033C, HHSN261201000034C, HHSN261201000035C, HHSN261201000029C, HHSN261201000031C, HHSN261201000028C, and HHSN261201000030C.
Compliance with ethical standards
Conflict of interest
The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
- 1.Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. Accessed 21 March 2017
- 2.Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25(10):1901–1914. https://doi.org/10.1093/annonc/mdu042 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Walker GV, Grant SR, Guadagnolo BA, Hoffman KE, Smith BD, Koshy M, Allen PK, Mahmood U (2014) Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol 32(28):3118–3125. https://doi.org/10.1200/jco.2014.55.6258 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N (2015) Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. https://doi.org/10.1016/s1470-2045(15)00041-8 PubMedPubMedCentralCrossRefGoogle Scholar
- 9.Akinyemiju T, Moore JX, Ojesina AI, Waterbor JW, Altekruse SF (2016) Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources. Breast Cancer Res Treat 157(3):575–586. https://doi.org/10.1007/s10549-016-3840-x CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Sheppard VB, Oppong BA, Hampton R, Snead F, Horton S, Hirpa F, Brathwaite EJ, Makambi K, Onyewu S, Boisvert M, Willey S (2015) Disparities in breast cancer surgery delay: the lingering effect of race. Ann Surg Oncol 22(9):2902–2911. https://doi.org/10.1245/s10434-015-4397-3 CrossRefPubMedGoogle Scholar
- 13.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v2.2017Google Scholar
- 14.Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M (2015) Surgery of the primary tumor in de novo metastatic breast cancer: to do or not to do? Eur J Surg Oncol 41(10):1288–1292. https://doi.org/10.1016/j.ejso.2015.07.013 CrossRefPubMedGoogle Scholar
- 19.National Cancer Institute. Surveillance, epidemiology, and end results program. Algorithm for derived HER2 summary variable. https://seer.cancer.gov/seerstat/databases/ssf/her2-derived.html. Accessed 19 Sept 2017
- 20.Griggs JJ, Hawley ST, Graff JJ, Hamilton AS, Jagsi R, Janz NK, Mujahid MS, Friese CR, Salem B, Abrahamse PH, Katz SJ (2012) Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol 30(25):3058–3064. https://doi.org/10.1200/jco.2012.41.9564 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Lipscomb J, Gillespie TW, Goodman M, Richardson LC, Pollack LA, Ryerson AB, Ward KC (2012) Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. Breast Cancer Res Treat 133(1):285–296. https://doi.org/10.1007/s10549-011-1916-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Silva A, Rauscher GH, Hoskins K, Rao R, Ferrans CE (2013) Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines. Breast Cancer Res Treat 142(3):667–672. https://doi.org/10.1007/s10549-013-2759-8 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Wu XC, Lund MJ, Kimmick GG, Richardson LC, Sabatino SA, Chen VW, Fleming ST, Morris CR, Huang B, Trentham-Dietz A, Lipscomb J (2012) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30(2):142–150. https://doi.org/10.1200/jco.2011.36.8399 CrossRefPubMedGoogle Scholar
- 28.Freedman RA, He Y, Winer EP, Keating NL (2013) Racial/ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? Health Serv Res 48(5):1669–1683. https://doi.org/10.1111/1475-6773.12063 PubMedPubMedCentralCrossRefGoogle Scholar
- 29.McLaughlin JM, Anderson RT, Ferketich AK, Seiber EE, Balkrishnan R, Paskett ED (2012) Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 30(36):4493–4500. https://doi.org/10.1200/jco.2012.39.7695 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong Y-N, Loftus LS, Breslin TM, Hudis CA, Javid SH, Rugo HS, Silver SM, Lepisto EM, Weeks JC (2013) Time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions. JNCI: J Natl Cancer Inst 105(2):104–112. https://doi.org/10.1093/jnci/djs506 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Wheeler SB, Carpenter WR, Peppercorn J, Schenck AP, Weinberger M, Biddle AK (2012) Predictors of timing of adjuvant chemotherapy in older women with hormone receptor-negative, stages II–III breast cancer. Breast Cancer Res Treat 131(1):207–216. https://doi.org/10.1007/s10549-011-1717-6 CrossRefPubMedGoogle Scholar
- 32.Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH (2008) Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26(30):4891–4898. https://doi.org/10.1200/jco.2007.14.1168 CrossRefPubMedPubMedCentralGoogle Scholar
- 35.U.S. Bureau of Census. Geographic areas reference manual. U.S. Bureau of Census, Suitland, 1994. https://www.census.gov/geo/reference/garm.html. Accessed 18 July 2017